Inventor

LABERGE REMI-MARTIN

US24 patents

⚠️ This page may combine multiple inventors who share the name “LABERGE REMI-MARTIN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

LABERGE REMI-MARTIN

BUCK INST RES AGING

Treatment of ophthalmic conditions by selectively removing senescent cells from the eye

Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2

Unit dose of a cis-imidazoline for treating an osteoarthritic joint by removing senescent cells

Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye

Treatment for osteoarthritis by intra-articular administration of a cis-imidazoline

Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells

Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen

Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population

Use of sulfonamide inhibitors of Bcl-2 to treat senescence-associated lung conditions such as pulmonary fibrosis and chronic obstructive pulmonary disease

Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders using an inhibitor of Akt kinase

Treating liver disease by selectively eliminating senescent cells

Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissue

Treating cardiovascular disease by selectively eliminating senescent cells

Inhibiting activity of senescent cells using a glucocorticoid

Transgenic mouse for determining the role of senescent cells in cancer

Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitor

Nucleic acid construct with a p16 promoter that causes a prodrug converting enzyme to be expressed specifically in senescent cells

UNITY BIOTECHNOLOGY INC

Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells

Treatment of joint pain

Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (PI3K) inhibitor

Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss

Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer

Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer

MAYO FOUND MEDICAL EDUCATION & RES

Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques